TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38225579

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 17.5 mg weekly by subcutaneous injection for 12 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 40
Study: 38225589

Group type: EXPERIMENTAL
Intervention: Gabapentin, sulfasalazine, memantine and chemoradiotherapy (Arm A)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Chemoradiotherapy alone (Arm B)
Number of subjects: 120
Study: 38225598

Group type: EXPERIMENTAL
Intervention: High dose oral favipiravir (3.6g on day 0 followed by 1.6g daily for 7 days)
Number of subjects: 240

Group type: COMPARATOR
Intervention: No study drug (Control)
Number of subjects: 240
Study: 38225633

Group type: EXPERIMENTAL
Intervention: Task shifting for TCD screening
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Task shifting
Number of subjects: 7
Study: 38225650

Group type: EXPERIMENTAL
Intervention: Sequential levofloxacin-based treatment regimen
Number of subjects: 300

Group type: COMPARATOR
Intervention: Concomitant levofloxacin-based regimen
Number of subjects: 300

Group type: COMPARATOR
Intervention: High-dose dual therapy (proton-pump inhibitor and amoxicillin)
Number of subjects: 300
Study: 38225677

Group type: EXPERIMENTAL
Intervention: Adapted TranS-C
Number of subjects: 154

Group type: COMPARATOR
Intervention: Standard TranS-C
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Provider perceptions of fit
Number of subjects: 154
Study: 38225952

Group type: EXPERIMENTAL
Intervention: 300 IR HDM SLIT tablet
Number of subjects: 818

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 818
Study: 38225983

Group type: EXPERIMENTAL
Intervention: Hypoperfusion-hypodensity mismatch
Number of subjects: 247

Group type: COMPARATOR
Intervention: Automated perfusion mismatch
Number of subjects: 247
Study: 38226285

Group type: EXPERIMENTAL
Intervention: Extracorporeal carbon dioxide removal (ECCO)
Number of subjects: 8
Study: 38226445

Group type: EXPERIMENTAL
Intervention: Universal HIV-test-and-treat intervention
Number of subjects: 90801

Group type: COMPARATOR
Intervention: Control (population-level HIV testing at baseline and endline)
Number of subjects: 90801
Study: 38226491

Group type: EXPERIMENTAL
Intervention: Two-tiered intervention involving training in palliative care and a new consultation model, with medical consultations every 3 weeks for 12 weeks.
Number of subjects: 53
Study: 38226507

Group type: EXPERIMENTAL
Intervention: Mobile application with just-in-time adaptive intervention promoting physical activity and lower-sodium food choices, including weekly goal setting.
Number of subjects: 484

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: Mobile application notifications.
Number of subjects: 484
Study: 38226511

Group type: EXPERIMENTAL
Intervention: Corrie Hybrid CR program combined with usual care CR
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care CR alone
Number of subjects: 200
Study: 38226512

Group type: EXPERIMENTAL
Intervention: Text message-based mHealth intervention
Number of subjects: 17
Study: 38226931

Group type: EXPERIMENTAL
Intervention: N-803 plus BCG therapy
Number of subjects: 164
Study: 38227007

Group type: EXPERIMENTAL
Intervention: 2-back task
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1-back task
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Verbal fluency test (VFT)
Number of subjects: 60
Study: 38227032

Group type: EXPERIMENTAL
Intervention: Default palliative care consultation
Number of subjects: 24065

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 24065
Study: 38227033

Group type: EXPERIMENTAL
Intervention: Toripalimab + chemotherapy
Number of subjects: 501

Group type: COMPARATOR
Intervention: Placebo + chemotherapy
Number of subjects: 501
Study: 38227034

Group type: EXPERIMENTAL
Intervention: Nurse and social worker palliative telecare team (6 phone calls with a nurse for symptom management and 6 phone calls with a social worker for psychosocial care).
Number of subjects: 306

Group type: COMPARATOR
Intervention: Usual care (educational handout for self-care).
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Nurse and social worker palliative telecare team.
Number of subjects: 306
Study: 38227308

Group type: EXPERIMENTAL
Intervention: MultiStem (1.2 billion cells, intravenous)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Placebo (intravenous)
Number of subjects: 206
Study: 38227315

Group type: EXPERIMENTAL
Intervention: Health literacy-informed discharge medication communication bundle (n=99)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Standard counseling (n=99)
Number of subjects: 198
Study: 38227355

Group type: EXPERIMENTAL
Intervention: Metaverse group (exercise video distribution in metaverse space)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: YouTube group (exercise video distribution via YouTube)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no special instructions)
Number of subjects: 48
Study: 38227362

Group type: EXPERIMENTAL
Intervention: iDBT (immediate access group)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: iDBT (both groups)
Number of subjects: 72

Group type: COMPARATOR
Intervention: iDBT (delayed access group)
Number of subjects: 72
Study: 38227447

Group type: EXPERIMENTAL
Intervention: Intensification of antihypertensive therapy with maximally tolerated doses of a β-blocker, a long-acting dihydropyridine calcium channel blocker, and a renin-angiotensin system inhibitor.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diet and dialysate restricted in sodium to facilitate achievement of dry weight.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adequate time on dialysis of at least 4 hours for delivering an adequate dialysis dose.
Number of subjects: 0
Study: 38227538

Group type: EXPERIMENTAL
Intervention: Magnetic resonance-guided focused ultrasound thalamotomy
Number of subjects: 10
Study: 38227621

Group type: EXPERIMENTAL
Intervention: Liraglutide 3.0 mg/d
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 38227687

Group type: EXPERIMENTAL
Intervention: Summed stress score
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Hyperemic myocardial blood flow (MBF)
Number of subjects: 400
Study: 38227697

Group type: EXPERIMENTAL
Intervention: Coronary sinus narrowing via reducer implantation
Number of subjects: 24
Study: 38227830

Group type: EXPERIMENTAL
Intervention: N2-N3 sleep EEG power in delta (0.5-4 Hz)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Slow delta power (0.5-1 Hz)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Fast delta power (1-4 Hz)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Delta power (all frequency bands)
Number of subjects: 127
Study: 38227898

Group type: EXPERIMENTAL
Intervention: Lenvatinib plus Pembrolizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 0
Study: 38227933

Group type: EXPERIMENTAL
Intervention: High-dose vitamin A (4000 IU/kg, maximum 250,000 IU)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 38227934

Group type: EXPERIMENTAL
Intervention: ANA-associated AIC with ANA titer ≥1/160
Number of subjects: 1803

Group type: EXPERIMENTAL
Intervention: ANA-associated AIC with ANA titer >1/160
Number of subjects: 1803

Group type: EXPERIMENTAL
Intervention: Age >10 years at AIC diagnosis
Number of subjects: 1803

Group type: COMPARATOR
Intervention: ANA-negative test
Number of subjects: 1803

Group type: EXPERIMENTAL
Intervention: Severe manifestations of SLE
Number of subjects: 1803
Study: 38227963

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 450

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450
Study: 38228054

Group type: EXPERIMENTAL
Intervention: 5C participants
Number of subjects: 115

Group type: COMPARATOR
Intervention: OACC patients
Number of subjects: 115
Study: 38228287

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA (onabotA)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 75
Study: 38228387

Group type: EXPERIMENTAL
Intervention: Combined standard medical treatment (SMT) and endovascular thrombectomy (EVT)
Number of subjects: 221
Study: 38228467

Group type: EXPERIMENTAL
Intervention: Implementation of a familial hypercholesterolemia (FH) screening program in primary care.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Barriers to FH screening implementation.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Facilitators for FH screening implementation.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Refined implementation strategy package for FH screening.
Number of subjects: 0
Study: 38229072

Group type: EXPERIMENTAL
Intervention: Higher protein dose
Number of subjects: 1277
Study: 38229112

Group type: EXPERIMENTAL
Intervention: N-terminal titin fragment measurement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Creatine kinase (CK) measurement
Number of subjects: 0
Study: 38229143

Group type: EXPERIMENTAL
Intervention: Bi-modal 12-week hatha yoga program (2 60-min group classes a week)
Number of subjects: 0
Study: 38229181

Group type: EXPERIMENTAL
Intervention: Transdiagnostic sleep treatment (six sessions)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Sleep hygiene education (single session)
Number of subjects: 88
Study: 38229197

Group type: EXPERIMENTAL
Intervention: Ketogenic diet (KD)
Number of subjects: 6

Group type: COMPARATOR
Intervention: High-carbohydrate diet (HCD)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Habitual diet (HD)
Number of subjects: 6
Study: 38229199

Group type: EXPERIMENTAL
Intervention: 20 mg octreotide subcutaneous depot (CAM2029) every 2 weeks (Q2W)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Investigator's choice of SRL therapy at standard doses (octreotide LAR 30 mg or lanreotide ATG 120 mg every 4 weeks [Q4W])
Number of subjects: 300
Study: 38229269

Group type: EXPERIMENTAL
Intervention: Damoctocog alfa pegol (BAY 94-9027, Jivi) at 45 IU/kg every 5 days or 40 IU/kg twice-weekly
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Damoctocog alfa pegol (BAY 94-9027, Jivi)
Number of subjects: 36
Study: 38229349

Group type: EXPERIMENTAL
Intervention: Attainment of lupus low disease activity state (LLDAS) at any timepoint
Number of subjects: 1707

Group type: EXPERIMENTAL
Intervention: Cumulative time in LLDAS
Number of subjects: 1707

Group type: EXPERIMENTAL
Intervention: Increased durations of sustained LLDAS
Number of subjects: 1707
Study: 38229356

Group type: COMPARATOR
Intervention: Tofacitinib monotherapy (masked methotrexate withdrawal)
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Tofacitinib plus methotrexate
Number of subjects: 533
Study: 38229357

Group type: EXPERIMENTAL
Intervention: IBI303 (40 mg subcutaneous injection every 2 weeks)
Number of subjects: 438

Group type: COMPARATOR
Intervention: Adalimumab (40 mg subcutaneous injection every 2 weeks)
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: IBI303 (per-protocol population)
Number of subjects: 438

Group type: COMPARATOR
Intervention: Adalimumab (per-protocol population)
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: IBI303
Number of subjects: 438

Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 438
Study: 38229377

Group type: EXPERIMENTAL
Intervention: Anifrolumab 300 mg
Number of subjects: 457

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 457
Study: 38229392

Group type: EXPERIMENTAL
Intervention: Probiotic treatment with three Lactobacillus strains (Lactobacillus paracasei DSM 13434, Lactobacillus plantarum DSM 15312, Lactobacillus plantarum DSM 15313; 1 x 10^9 CFU)
Number of subjects: 249

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 249
Study: 38229519

Group type: EXPERIMENTAL
Intervention: Inertial Measurement Units during the 6-Minute Walking Test (6MWT)
Number of subjects: 72
Study: 38229914

Group type: EXPERIMENTAL
Intervention: Inhaled anesthetics after total intravenous anesthesia (TIVA)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Total intravenous anesthesia (TIVA)
Number of subjects: 1
Study: 38230727

Group type: EXPERIMENTAL
Intervention: Web-based cognitive games or Web-based crossword puzzles
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: CCT cohort (Computerized Cognitive Training)
Number of subjects: 105
Study: 38230875

Group type: EXPERIMENTAL
Intervention: Costal chondrocyte-derived pellet-type autologous chondrocyte implantation (CCP-ACI)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Microfracture
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: CCP-ACI
Number of subjects: 25
Study: 38231017

Group type: EXPERIMENTAL
Intervention: Prednisone (PDN) 1 mg/kg per day from days 0 to 28 (Arm A)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: High-dose dexamethasone (HD-DXM) 40 mg per day for 4 days, every 14 days, for 3 consecutive courses (Arm B)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Prednisone (PDN)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: High-dose dexamethasone (HD-DXM)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Overall disease-free survival
Number of subjects: 113
Study: 38231079

Group type: EXPERIMENTAL
Intervention: Telmisartan (40 mg daily for 14 days) plus standard of care
Number of subjects: 66

Group type: COMPARATOR
Intervention: Standard of care alone
Number of subjects: 66
Study: 38231126

Group type: EXPERIMENTAL
Intervention: Guadecitabine
Number of subjects: 302

Group type: COMPARATOR
Intervention: TC (treatment choice)
Number of subjects: 302
Study: 38231282

Group type: EXPERIMENTAL
Intervention: Low pneumoperitoneum (Pnp) of 7 mmHg
Number of subjects: 98

Group type: COMPARATOR
Intervention: Standard pneumoperitoneum (Pnp) of 12 mmHg
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Both groups (Low Pnp and Standard Pnp)
Number of subjects: 98
Study: 38231313

Group type: EXPERIMENTAL
Intervention: STRIDE intervention
Number of subjects: 100
Study: 38231361

Group type: EXPERIMENTAL
Intervention: Economic empowerment intervention (long-term child development account, micro-enterprise workshops, educational sessions)
Number of subjects: 455

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 455
Study: 38231380

Group type: EXPERIMENTAL
Intervention: Robotic intervention programme
Number of subjects: 60

Group type: COMPARATOR
Intervention: Human-instructed programme
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 38231502

Group type: EXPERIMENTAL
Intervention: Single-port robotic nipple-sparing mastectomy (SPrNSM)
Number of subjects: 20
Study: 38231511

Group type: EXPERIMENTAL
Intervention: Behavioral Activation Psychotherapy (BA)
Number of subjects: 416

Group type: COMPARATOR
Intervention: Antidepressant Medication Management (MEDS)
Number of subjects: 416
Study: 38231536

Group type: EXPERIMENTAL
Intervention: 8-week blended intervention combining weekly face-to-face group sessions and a digital companion app
Number of subjects: 16
Study: 38231552

Group type: EXPERIMENTAL
Intervention: CCBT (n=301)
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: CCBT plus OHC (n=302)
Number of subjects: 603

Group type: COMPARATOR
Intervention: Usual care (n=101)
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: CCBT
Number of subjects: 603

Group type: EXPERIMENTAL
Intervention: OHC
Number of subjects: 603
Study: 38231570

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) intervention, trialed 1 to 2 weeks preoperatively, average engagement time 12 minutes.
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control group (treatment as usual).
Number of subjects: 7
Study: 38231576

Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 1341

Group type: COMPARATOR
Intervention: Vitamin K Antagonists (VKA)
Number of subjects: 1341
Study: 38231588

Group type: EXPERIMENTAL
Intervention: Thermal central sensitization (CS) induction protocol
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Nociceptive withdrawal reflex magnitude (NWR-M)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Nociceptive withdrawal reflex response rate (NWR-RR) at the rectus femoris
Number of subjects: 66

Group type: COMPARATOR
Intervention: Sham protocol
Number of subjects: 66
Study: 38231590

Group type: EXPERIMENTAL
Intervention: Urinary CD4 + T-cell counts
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Combination of urinary CD4 + T-cell counts with proteinase-3 ANCA levels
Number of subjects: 102
Study: 38231621

Group type: EXPERIMENTAL
Intervention: Testosterone gel applied daily
Number of subjects: 5204

Group type: COMPARATOR
Intervention: Placebo gel applied daily
Number of subjects: 5204
Study: 38231623

Group type: EXPERIMENTAL
Intervention: Azithromycin (20 mg per kilogram of body weight)
Number of subjects: 32877

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32877
Study: 38231622

Group type: EXPERIMENTAL
Intervention: CRT defibrillator (CRT-D)
Number of subjects: 1050

Group type: COMPARATOR
Intervention: Implantable cardioverter-defibrillators (ICD)
Number of subjects: 1050
Study: 38231624

Group type: EXPERIMENTAL
Intervention: Simnotrelvir plus ritonavir (750 mg of simnotrelvir plus 100 mg of ritonavir, twice daily for 5 days)
Number of subjects: 1208

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1208

Group type: EXPERIMENTAL
Intervention: Simnotrelvir plus ritonavir
Number of subjects: 1208
Study: 38231777

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd)
Number of subjects: 17
Study: 38232095

Group type: EXPERIMENTAL
Intervention: qSOFA score
Number of subjects: 2851

Group type: EXPERIMENTAL
Intervention: SIRS criteria
Number of subjects: 2851

Group type: EXPERIMENTAL
Intervention: NEWS/NEWS2/MEWS
Number of subjects: 2851
Study: 38232100

Group type: EXPERIMENTAL
Intervention: Healthy lifestyle education intervention (six weeks of fortnightly six sessions, 45 minutes per session)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Control group (regular curriculums and normal physical activity routines)
Number of subjects: 250
Study: 38232249

Group type: EXPERIMENTAL
Intervention: Maintenance electroconvulsive therapy (M-ECT) with medication
Number of subjects: 56

Group type: COMPARATOR
Intervention: Medication only
Number of subjects: 56
Study: 38232336

Group type: EXPERIMENTAL
Intervention: Measurable residual disease (MRD) detection using targeted next-generation sequencing (NGS) panel and droplet digital polymerase chain reaction (ddPCR)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: MRD+ (positive measurable residual disease)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: MRD+ patients with chronic GVHD
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Cutoff levels of MRD (0.1%, 0.3%, 0.5%)
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Positive BM MRD
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Continuous complete remission (CCR)
Number of subjects: 266
Study: 38232337

Group type: EXPERIMENTAL
Intervention: Histology-tailored (HT) regimen
Number of subjects: 101

Group type: COMPARATOR
Intervention: Standard (S) anthracycline + ifosfamide (AI) regimen
Number of subjects: 101
Study: 38232341

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus paclitaxel (GEMPAX)
Number of subjects: 211

Group type: COMPARATOR
Intervention: Gemcitabine alone
Number of subjects: 211
Study: 38232682

Group type: EXPERIMENTAL
Intervention: Fermented yogurt products
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Non-fermented milk products
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: All intervention products (fermented and non-fermented)
Number of subjects: 100
Study: 38232692

Group type: EXPERIMENTAL
Intervention: High BAT volume (≥20 mL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low BAT volume (<20 mL)
Number of subjects: 0
Study: 38232698

Group type: EXPERIMENTAL
Intervention: Early time-restricted eating (eTRE) schedule (0800 to 1400)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control eating schedule (0800 to 2000)
Number of subjects: 16
Study: 38232714

Group type: EXPERIMENTAL
Intervention: Stroke Impact Scale (SIS) version 3.0
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Hospital Anxiety and Depression Scale (HADS)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: NIHSS score, age, and depression
Number of subjects: 158
Study: 38232864

Group type: EXPERIMENTAL
Intervention: Psychological pain treatments
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Composite scores from 4 days of ratings
Number of subjects: 164
Study: 38233009

Group type: EXPERIMENTAL
Intervention: Apremilast
Number of subjects: 59
Study: 38233017

Group type: EXPERIMENTAL
Intervention: Elevated symptoms of anxiety (HADS-A)
Number of subjects: 3815

Group type: EXPERIMENTAL
Intervention: Elevated symptoms of depression (HADS-D)
Number of subjects: 3815

Group type: EXPERIMENTAL
Intervention: Elevated symptoms of both anxiety and depression
Number of subjects: 3815

Group type: EXPERIMENTAL
Intervention: Quality of Life (QOL) and Health Status (HS)
Number of subjects: 3815
Study: 38233049

Group type: EXPERIMENTAL
Intervention: Perceived injustice-targeted pain neuroscience education (PNE)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Biomedically focused pain education
Number of subjects: 156
Study: 38233053

Group type: EXPERIMENTAL
Intervention: Laparoscopic myomectomy
Number of subjects: 101008

Group type: EXPERIMENTAL
Intervention: Open myomectomy
Number of subjects: 101008

Group type: EXPERIMENTAL
Intervention: Laparoscopic hysterectomy
Number of subjects: 101008

Group type: EXPERIMENTAL
Intervention: Hysterectomy
Number of subjects: 101008

Group type: EXPERIMENTAL
Intervention: High-frequency MRI-guided focused ultrasound surgery (MRgFUS)
Number of subjects: 101008

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 101008

Group type: EXPERIMENTAL
Intervention: Myomectomy
Number of subjects: 101008

Group type: EXPERIMENTAL
Intervention: MRgFUS
Number of subjects: 101008
Study: 38233075

Group type: EXPERIMENTAL
Intervention: Diurnal cortisol production in patients with RA
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Treatment-induced minimal disease activity (MDA) at 6 months
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Baseline morning cortisol levels
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Baseline ACTH levels
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Baseline morning cortisol <13.9 nmol/L
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Individualised diurnal cortisol production
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Disturbed circadian cortisol rhythm at baseline
Number of subjects: 28
Study: 38233083

Group type: EXPERIMENTAL
Intervention: Nebulised normal saline (NS)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Nasal irrigation with normal saline (NS)
Number of subjects: 300

Group type: COMPARATOR
Intervention: No saline therapy
Number of subjects: 300